Match!
Dong Hoon Lee
Yonsei University
Molecular biologyHDAC6EpigeneticsCancer researchBiology
30Publications
7H-index
168Citations
What is this?
Publications 21
Newest
#1Hyunji Lee (CNU: Chungnam National University)H-Index: 10
#2Youngeun Hong (CNU: Chungnam National University)H-Index: 4
Last. Seon-Hwan Kim (CNU: Chungnam National University)H-Index: 7
view all 13 authors...
The development of skeletal muscle requires progression of a highly ordered cascade of events comprising myogenic lineage commitment, myoblast proliferation, and terminal differentiation. The process of myogenesis is controlled by several myogenic transcription factors that act as terminal effectors of signaling cascades and produce appropriate developmental stage-specific transcripts. PHD finger protein 20 (PHF20) is a multidomain protein and subunit of a lysine acetyltransferase complex that a...
Source
#1Go Woon Kim (Yonsei University)H-Index: 2
#2Jung Yoo (Yonsei University)H-Index: 1
Last. So Hee Kwon (Yonsei University)H-Index: 18
view all 8 authors...
Abstract Multiple Myeloma (MM) is a hematological malignancy of plasma cells. Although advanced therapies have elevated MM survival rate, MM eventually relapses. Relapsed/refractory MM (R/R MM) cells gain resistance to previously used drugs, which reduces treatment options. In this study, we propose a newly synthesized HDAC6-selective inhibitor, A452, as a strategy to overcome resistance to immunomodulatory drugs (IMiDs), the principal MM therapeutic drugs. Here, we identified that A452 alone re...
Source
#1Jung Yoo (Yonsei University)H-Index: 1
#2Yu Hyun Jeon (Yonsei University)H-Index: 1
Last. So Hee Kwon (Yonsei University)H-Index: 18
view all 7 authors...
Lysine-specific histone demethylase 3 (KDM3) subfamily proteins are H3K9me2/me1 histone demethylases that promote gene expression. The KDM3 subfamily primarily consists of four proteins (KDM3A−D). All four proteins contain the catalytic Jumonji C domain (JmjC) at their C-termini, but whether KDM3C has demethylase activity is under debate. In addition, KDM3 proteins contain a zinc-finger domain for DNA binding and an LXXLL motif for interacting with nuclear receptors. Of the KDM3 proteins, KDM3A ...
Source
#1Sang Ah Yi (SKKU: Sungkyunkwan University)H-Index: 6
#2Dong Hoon Lee (Yonsei University)H-Index: 7
Last. 이지은 ( Ji Eun Lee ) (SKKU: Sungkyunkwan University)H-Index: 14
view all 18 authors...
E6 oncoprotein derived from high-risk human papillomavirus (HPV) drives the development of cervical cancer through p53 degradation. Because cervical cancer therapies to inactivate HPV or E6 protein are not available, alternative strategies are required. Here, we show that HPV-mediated nuclear export of human heterochromatin protein 1γ (HP1γ) reduces the stability of p53 through UBE2L3-mediated p53 polyubiquitination during cervical cancer progression. In general, HP1 plays a key role in heteroch...
Source
#1Dong Hoon Lee (Yonsei University)H-Index: 7
#2Go Woon Kim (Yonsei University)H-Index: 2
Last. So Hee Kwon (Yonsei University)H-Index: 18
view all 6 authors...
The KDM4 subfamily H3K9 histone demethylases are epigenetic regulators that control chromatin structure and gene expression by demethylating histone H3K9, H3K36, and H1.4K26. The KDM4 subfamily mainly consists of four proteins (KDM4A-D), all harboring the Jumonji C domain (JmjC) but with differential substrate specificities. KDM4A-C proteins also possess the double PHD and Tudor domains, whereas KDM4D lacks these domains. KDM4 proteins are overexpressed or deregulated in multiple cancers, cardio...
2 CitationsSource
#1Hye Rim Won (Yonsei University)H-Index: 5
#2Dong Hoon Lee (Yonsei University)H-Index: 7
Last. So Hee Kwon (Yonsei University)H-Index: 18
view all 6 authors...
: Nonselective histone deacetylase (HDAC) inhibitors have therapeutic effects, but exhibit dose‑limiting toxicities in patients with multiple myeloma (MM). The present study investigated the interaction between the HDAC6 inhibitor, A452, and immunomodulatory drugs (IMiDs) on dexamethasone (Dex)‑sensitive and ‑resistant MM cells compared with the current clinically tested HDAC6 inhibitor, ACY‑1215. It was shown that the combination of the HDAC6‑selective inhibitor, A452, with either of the IMiDs ...
Source
#1Dong Hoon LeeH-Index: 7
#2Go Woon KimH-Index: 2
Last. So Hee KwonH-Index: 18
view all 3 authors...
: Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL) with genetic alterations of BCL-2, KMT2B, and KMT6. FL is refractory to conventional chemotherapy and is still incurable in most patients. Thus, new drugs and/or novel combination treatment strategies are needed to further improve FL patient outcome. We investigated the efficacy of the histone deacetylase 6 (HDAC6) inhibitor A452 combined with a Bruton's tyrosine kinase (BTK) inhibitor ibrutinib on NHL and t...
1 CitationsSource
#1Dong Hoon Lee (Yonsei University)H-Index: 7
#2Hyun Wook Ryu (Yonsei University)H-Index: 8
Last. So Hee Kwon (Yonsei University)H-Index: 18
view all 4 authors...
Heterochromatin protein 1 (HP1) is an epigenetic regulator of chromatin structure and genome function in eukaryotes. Despite shared features, most eukaryotes have minimum three HP1 homologs with differential localization patterns and functions. Most studies focus on Drosophila HP1a, and little is known about the properties of HP1b and HP1c. To determine the features of the three HP1 homologs, we performed the first comprehensive comparative analysis of Drosophila HP1 homologs. HP1 differentially...
1 CitationsSource
#1Hye Rim WonH-Index: 5
#2Hyun Wook RyuH-Index: 8
Last. So Hee KwonH-Index: 18
view all 6 authors...
: Although histone deacetylase inhibitors (HDACi) alone could be clinically useful, these are most recently used in combination with other anticancer agents in clinical trials for cancer treatment. Recently, we reported the anticancer activity of an HDAC6-selective inhibitor A452 toward various cancer cell types. This study aims to present a potent synergistic antiproliferative effect of A452/anticancer agent treatment in colorectal cancer cells (CRC) cells, independently of the p53 status. A452...
2 CitationsSource
#1Dong Hoon Lee (Yonsei University)H-Index: 7
#2Hye Rim Won (Yonsei University)H-Index: 5
Last. So Hee Kwon (Yonsei University)H-Index: 18
view all 5 authors...
: ACY‑1215, also known as ricolinostat, is a leading histone deacetylase 6 inhibitor, which is currently being tested in clinical trials for hematological malignancies. Previous studies have reported that ACY‑1215 is not potent enough as a monotherapy for the treatment of colorectal cancer (CRC), which generally requires combination therapy for successful treatment. Therefore, the present study aimed to determine whether the synergistic interaction detected between ACY‑1215 and anticancer agents...
5 CitationsSource
123